On December 12, 2013, Quintiles Transnational Holdings Inc. (Quintiles) announced that it has appointed W. Scott Evangelista as its President for Integrated Commercial Services and Solutions. The Company said that in this new role, Evangelista is responsible for leading Quintiles' global Commercial organization and the ongoing development and delivery of its related service offerings. Prior to Quintiles, Evangelista was a principal at Deloitte Consulting LLP's LifeSciences practice, where he served as commercial practice leader. Commenting on the appointment, Tom Pike, CEO of Quintiles said, "Scott's experience working on and developing innovative commercial solutions for the biopharmaceutical industry is a tremendous addition to our already world-class team. During his career, Scott has been involved in many aspects of the commercial organization, all while delivering a consistent track record of growth and innovation. He brings a range of expertise and experience that I believe will help take our commercial customer support to the next level." The Full Research Report on Quintiles Transnational Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

On December 11, 2013, CR Bard Inc.'s (CR Bard) Board of Directors declared a regular quarterly dividend of $0.21 per share on Bard's common stock. According to the Company, the current dividend indicated an annual dividend rate of $0.84 per share. The aforesaid dividend is payable on January 31, 2014 to shareholders of record at the close of business on January 21, 2014. The Full Research Report on CR Bard Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

On December 6, 2013, Theravance Inc. (Theravance) announced positive results from a phase III efficacy and safety study of fluticasone furoate "FF"/vilanterol "VI" designed to support a potential filing for an asthma indication for adults in the US. The Company said that these results will inform GSK's discussions with the FDA on the regulatory requirements of an asthma indication for FF/VI in the US. Theravance CEO Rick E. Winningham said, "There is an ongoing unmet medical need among patients with asthma. This is an important outcome for FF/VI and we will continue working with GSK to determine how we can make this potential treatment available to appropriate patients who could benefit from a new asthma medicine." The Full Research Report on Theravance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

On December 9, 2013, Immunomedics Inc. (Immunomedics) announced promising activity with veltuzumab in relapsed immune thrombocytopenia. Immunomedics said that veltuzumab, administered subcutaneously as a single agent, produced an overall objective response rate of 49% in 47 evaluable patients with relapsed immune thrombocytopenia (ITP), including 15 patients (32%) who reported a complete response. For the 23 patients who responded, median time to relapse from initial veltuzumab dose was 9.2 months, with 11 patients (48%) maintaining their response for more than 1 year. Further, the Company said that Veltuzumab showed activity across all dose levels tested, including the lowest dose of 80 mg x 2, and was active in patients with limited disease duration of 1 year or less, as well as in more heavily pretreated patients with chronic refractory disease. Cynthia L. Sullivan, President and CEO of the Company commented, "We are very pleased with these promising results. The fact that some patients relapsed to TPOR agonists responded to veltuzumab is particularly encouraging. We are currently evaluating various options for further clinical development of veltuzumab in this and other autoimmune disease indications, as well as in oncology, including licensing arrangements and collaborations with outside study groups." The Full Research Report on Immunomedics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

On December 6, 2013, Progenics Pharmaceuticals Inc. (Progenics Pharmaceuticals) presented findings from a Phase I study of its Imaging Agent, 1404, at the meeting of the Society for Urologic Oncology in Rockville, Maryland. The poster, entitled A Phase I Study of TC-99-M-MIP-1404 SPECT/CT to Identify and Localize High Grade Cancer in the Prostate Gland, was presented by Kevin Slawin, M.D., Director, Vanguard Urologic Institute, Memorial Hermann-TMC. Dr. Slawin said, "In this study, the presence of primary prostate cancer was correctly identified in eight of eight patients by SPECT/CT imaging with 1404. An imaging agent with this high degree of accuracy has the potential to allow doctors and their patients to focus on the treatment of aggressive cancers while more conservatively managing low grade cancers." The Full Research Report on Progenics Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.

Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

Join 150,000+ InsidersSIGN UP FOR OURNEWSLETTER

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join thousands of pharma industry leaders who get FiercePharma via daily email. Sign up today!

THE LIBRARY: WEBINAR

This webinar will summarize the core scientific concepts needed to develop a global observational study protocol that describes or evaluates a therapeutic treatment in patients under conditions of usual care, in terms of clinical, humanistic and economic outcomes for a variety of key stakeholders. Register Today!

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!